Bausch Health is a deeply discounted specialty pharma (forward P/E 1.9x, FCF yield 53.5%) with a strong beat streak and momentum, but the price is 18.3% above the analyst target and revenue depends heavily on a few products.
Thesis pillars
- Extreme Valuation And Fcf Yield↓Deteriorating
- Earnings Beat Momentum↑Improving
- Product Concentration Risk↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026, based on the 10-K filed Feb 19, 2026
Bausch Health Companies Inc. (BHC) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $8.14, but acceptable to hold if already in. Reasons: Concentration risk — Product: Xifaxan® (85.0%); Concentration risk — Product: Arestin® (95.0%).
Bausch Health develops specialty pharmaceuticals and medical devices across five segments—Salix (GI/hepatology), International, Solta Medical, Diversified, and Bausch + Lomb (eye health)—marketed in approximately 90 countries. Revenues totaled $10,266 million in 2025; Xifaxan®... Read more
Hold if already holding. Not a fresh buy at $8.14, but acceptable to hold if already in. Reasons: Concentration risk — Product: Xifaxan® (85.0%); Concentration risk — Product: Arestin® (95.0%). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.2/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 105d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated Oct 28, 2026Recent Developments — Bausch Health Companies Inc.
Latest news
- NEWS Earnings call transcript: Bausch Health tops Q3 2026 estimates, shares jump - Investing.com UK — Investing.com UK Oct 28, 2026 positive
- NEWS Bausch Health Companies Inc. authorizes a Buyback Plan. - www.marketscreener.com — www.marketscreener.com Oct 28, 2026 positive
- NEWS Bausch Health Companies Inc. announces an Equity Buyback for 5% of its issued share capital, for $50 million. - www.mark — www.marketscreener.com Oct 28, 2026 positive
- NEWS Bausch: Q3 Earnings Snapshot - KTVB — KTVB Oct 28, 2026 neutral
- NEWS Bausch: Q3 Earnings Snapshot - kare11.com — kare11.com Oct 28, 2026 neutral
Latest item Oct 28, 2026 · Generated 2026-11-04T11:34:30Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductXifaxan®85%10-K Item 1: 'Sales of the Xifaxan® product line currently represent approximately 85% of the Salix segment revenues.'
- HIGHProductArestin®95%10-K Item 1: 'Arestin® ... represents approximately 95% of Dentistry revenues'
- MEDIUMSupplierlimited number of sources for finished products and raw materials10-K Item 1A: 'our dependence on a limited number of sources for certain of our finished products and raw materials'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $8.14, but acceptable to hold if already in. Reasons: Concentration risk — Product: Xifaxan® (85.0%); Concentration risk — Product: Arestin® (95.0%). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Analyst target $6.96 reached (−14.5%), stop $7.57 (−7.5%), A.R:R -1.0:1. Score 6.2/10, moderate confidence.
Analyst target $6.96 reached (−14.5% from $8.14); no take-profit level is published. Analyst target $6.96 reached (−14.5%), stop $7.57 (−7.5%), A.R:R -1.0:1. Stop-loss: $7.57.
Concentration risk — Product: Xifaxan® (85.0%); Concentration risk — Product: Arestin® (95.0%); Analyst target reached - limited upside remaining.
Bausch Health Companies Inc. trades at a P/E of N/A (forward 1.9). TrendMatrix value score: 8.3/10. Verdict: Hold.
8 analysts rate BHC, with a consensus score of 2.4/5. 5 analysts publish price targets averaging $8.
What does Bausch Health Companies Inc. do?Bausch Health develops specialty pharmaceuticals and medical devices across five segments—Salix (GI/hepatology),...
Bausch Health develops specialty pharmaceuticals and medical devices across five segments—Salix (GI/hepatology), International, Solta Medical, Diversified, and Bausch + Lomb (eye health)—marketed in approximately 90 countries. Revenues totaled $10,266 million in 2025; Xifaxan® drives approximately 85% of Salix segment sales. The company holds approximately 88% of publicly traded Bausch + Lomb, which it is pursuing to separate.